专利悬崖边跳舞的跨国药企——从百时美施贵宝的“断臂求生”看全球药企的生存逻辑

药时代
07 Feb

正文共:1447字1图预计阅读时间:4分钟2024年4月,百时美施贵宝(BMS)宣布了一项15亿美元的“瘦身”计划,通过裁员、剥离非核心业务和关闭部分研发管线来应对业绩压力。不到一年后的2025年2月6日,这家跨国制药巨头再次宣布启动更大规模的“省钱之旅”,引发业界震动。BMS的连续行动不仅暴露了其自身困境,更折射出全球制药行业在专利悬崖、创新枯竭与资本压力下的集体焦虑。专利悬崖:悬在头顶的达摩...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10